Objective. To develop software to assess the potential aggressiveness of an incidentally detected renal mass using images. Methods. Thirty randomly selected patients who underwent nephrectomy for renal cell carcinoma (RCC) had their images independently reviewed by engineers. Tumor Roughness was based on image algorithm of tumor topographic features visualized on computed tomography (CT) scans. Univariant and multivariant statistical analyses are utilized for analysis. Results. We investigated 30 subjects that underwent partial or radical nephrectomy. After excluding poor image-rendered images, 27 patients remained (benign cyst=1, oncocytoma=2, clear cell RCC=15, papillary RCC=7, and chromophobe RCC=2). The mean roughness score for each mass is 1.18, 1.16, 1.27, 1.52, and 1.56 units, respectively (p<0.004). Renal masses were correlated with tumor roughness (Pearson's, p=0.02). However, tumor size itself was larger in benign tumors (p=0.1). Linear regression analysis noted that the roughness score is the most influential on the model with all other demographics being equal including tumor size (p=0.003). Conclusion. Using basic CT imaging software, tumor topography (roughness) can be quantified and correlated with histologies such as RCC subtype and could lead to determining aggressiveness of small renal masses.

INTRODUCTION AND OBJECTIVES: Radical nephrectomy (RN) with venous tumor thrombectomy (VTT) carries a significant morbidity and mortality risk. Closure of the inferior vena cava (IVC) can be performed with a patch/graft or can be closed primarily. We sought to examine the early outcomes of primary caval closure in this contemporary series. METHODS: We retrospectively reviewed the records of all patients who underwent RN with VTT between January 2013 and October 2017. Patients who had primary closure of the IVC were included. All patients received ASA post-operatively. Patients were followed until death or Jul 30, 2018. Chi-square test, t-test, and Fischer’s exact test were employed. RESULTS: Sixty-four patients underwent RN with VTT, of these fifty-two people had a Mayo Clinic level II tumor thrombus or higher. Five patients were excluded due to grafts or stapling off the cava. Of the remaining 47 patients the mean age and Charlson co-morbidity score were 60 and 2.6; overall 43% had metastatic disease on presentation. Majority of cases (66%) were right sided, 70% were level 3 or higher, 40% required venovenous/cardiopulmonary bypass, and 78% of patients had clear cell RCC. At a median follow-up 16.1 months, 17% developed caval occlusion. Two patients had IVC tumor recurrence, two patients had fibrosis of their IVC, and four developed thrombosis. The mean time caval occlusion was 13.3 months. IVC tumor recurrence was a poor outcome with both patients dying shortly after diagnosis. No variable predicted caval patency. Twenty one patients (45%) died with a median time of death of 10 months. Those with caval patency were less likely to die than those who developed IVC occlusion (28% vs 75%, p=0.0178). All level 4 thrombi cases were closed primarily, however, there was occlusion in 44% of cases vs 17% for infradiaphragmatic thrombectomy cases (p=0.09). CONCLUSIONS: Complex inferior vena cava reconstruction can be successfully avoided in most cases when managing venous tumor thrombectomy. Thrombosis occurs infrequently however, while not statistically significant, was more frequently encountered in supradiaphragmatic tumor thrombectomies. Source of Funding: CPRIT Grant Research Training Award (RP170345)

Introduction: Identify modifiable factors contributing to renal cell carcinoma in the PCLO to target disease prevention and reduce health care costs. Methods: The prostate, lung, colorectal, and ovarian database were queried for the primary outcome of kidney cancer. Demographics were investigated, specifically focusing on modifiable risk factors. Statistical analysis includes the Student t-test for continuous variables, chi-squared or Fisher's exact tests for dichotomous and categorical variables for bivariate analysis. The Cox proportional hazards model was used in a multivariate time-to-event analysis. Results: We investigate existing data relating specifically to renal cancer. After missing data were excluded, we analyzed 149,683 subjects enrolled in the prostate, lung, colorectal, and ovarian trial and noted 0.5% (n = 748) subjects developed renal cancer. Age, male gender, body mass index, diabetes, and hypertension were all significant associated with renal cancer in bivariate analysis (P < 0.05). Men have a significant increased risk of kidney cancer over women (hazard ratio [HR] = 1.85; 95% CI: 1.58-2.16; P < 0.0001). Nonmodifiable risk factors that are associated with kidney cancer include age (HR = 1.05; 95% CI: 1.01; 1.05, P = 0.001). Modifiable risk factors include obesity measured by body mass index (HR = 1.05; 95% CI: 1.02-1.07; P < 0.0001), hypertension (HR = 1.32; 95% CI: 1.13-1.54; P = 0.0004), and smoking in pack-years (HR = 1.04; 95% CI: 1.02-1.07; P = 0.0002). Conclusions: Obesity, hypertension, and smoking are the 3 modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma. Published by Elsevier Inc.

Introduction: Radical nephrectomy (RN) with venous tumour thrombectomy (VTT) carries a significant morbidity and mortality risk. Examination of a contemporary single-institution series permits the development of a management algorithm and an audit of its results. We report outcomes following the use of intraoperative colour Doppler ultrasound and our surgical pathway. Methods: We retrospectively reviewed the records of all patients who underwent RN with VTT for kidney cancer between January 1, 2013 and October 1, 2016. Surgical complications, postoperative complications (Clavien-Dindo classification >= 3), 90-day readmission rates, and outcomes are reported. Multivariate linear regression, logistic regression, and Cox proportional hazard modelling were used to identify associations. Results: Fifty-eight patients underwent RN with VTT. Of these, 26 (45%) patients had Mayo Clinic level III or IV thrombus and 19 required venovenous/cardiopulmonary bypass. Three patients required patch grafting. The median length of hospital stay was eight days and there were 20 major complications. The 30-day readmission rate was 21% and the 90-day mortality rate was 8.9%. In multivariate analysis, low serum albumin and age-adjusted Charlson comorbidity score predicted length of stay. Increased intraoperative blood loss was significantly associated with increasing body mass index, serum creatinine, tumour thrombus level, and a history of significant weight loss >9.1 kg. Low serum hematocrit predicted 90-day mortality. Conclusions: lntraoperative colour Doppler ultrasound is a useful tool and can facilitate caval preservation. Caval grafting can be avoided in most cases. Venovenous bypass can be avoided in many level III cases. Early therapeutic anticoagulation should be instituted with caution.

You have accessJournal of UrologyBladder Cancer: Detection & Screening1 Apr 2014MP22-15 NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR): PROGNOSTIC INDICATOR FOR OVERALL SURVIVAL (OS) IN PATIENTS UNDERGOING RADICAL CYSTECTOMY (RC) Reza Mehrazin, Daniel Canter, Brian Egleston, Daniel Parker, Zachary Piotrowski, Jeffrey J. Tomaszewski, Marc C. Smaldone, Paul Bloch, Kevan Iffrig, Philip Abbosh, Timothy Ito, Rosalia Viterbo, Richard E. Greenberg, David Y.T. Chen, Robert G. Uzzo, and Alexander Kutikov Reza MehrazinReza Mehrazin More articles by this author , Daniel CanterDaniel Canter More articles by this author , Brian EglestonBrian Egleston More articles by this author , Daniel ParkerDaniel Parker More articles by this author , Zachary PiotrowskiZachary Piotrowski More articles by this author , Jeffrey J. TomaszewskiJeffrey J. Tomaszewski More articles by this author , Marc C. SmaldoneMarc C. Smaldone More articles by this author , Paul BlochPaul Bloch More articles by this author , Kevan IffrigKevan Iffrig More articles by this author , Philip AbboshPhilip Abbosh More articles by this author , Timothy ItoTimothy Ito More articles by this author , Rosalia ViterboRosalia Viterbo More articles by this author , Richard E. GreenbergRichard E. Greenberg More articles by this author , David Y.T. ChenDavid Y.T. Chen More articles by this author , Robert G. UzzoRobert G. Uzzo More articles by this author , and Alexander KutikovAlexander Kutikov More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.863AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Inflammatory markers are known to predict outcomes in patients with hepatic, gastric, pancreatic, and kidney cancers. As such, we sought to confirm initial data regarding the prognostic relevance of preoperative NLR for OS in patients undergoing RC for urothelial carcinoma of bladder. METHODS We retrospectively analyzed our institutional, bladder cancer database and identified patients who underwent radical cystectomy from 2006 to 2011. Patients with available preoperative hematologic parameters for absolute lymphocyte and neutrophil count, within 1 month of RC, were included in the analysis. As previously reported, NLR≥2.5 was considered abnormal. Prognostic value of preoperative NLR was evaluated by univariate and multivariable Cox and Fine & Gray proportional hazard ratios to assist in risk stratification for OS. RESULTS 314 patients met eligibility criteria. Median follow-up was 29.5 months (IQR=38.8) . Majority of patients were Caucasian (90%) men (73%), with median age of 69. 32%,17%, 30%, 21%, and 22% had pathologic stage T1,T2,T3,T4, and node positive disease, respectively. While 49% received neoadjuvant chemotherapy, 35% of patients developed recurrent disease at a median follow-up of 10 months following RC. The 2- and 5- year OS rates were 72% and 41%, respectively. In multivariable analysis, independent of T-stage, N-stage, age, race, gender, receipt of chemotherapy, NLR>2.5 was associated with inferior overall survival (HR 1.8 [CI 1.2−2.7], p=0.007. CONCLUSIONS NLR is an independent prognostic factor in bladder cancer patients treated with RC . Further investigation into whether NLR can be harnessed for purposes of clinical prognostication and individualized patient care appears warranted. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e240 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Reza Mehrazin More articles by this author Daniel Canter More articles by this author Brian Egleston More articles by this author Daniel Parker More articles by this author Zachary Piotrowski More articles by this author Jeffrey J. Tomaszewski More articles by this author Marc C. Smaldone More articles by this author Paul Bloch More articles by this author Kevan Iffrig More articles by this author Philip Abbosh More articles by this author Timothy Ito More articles by this author Rosalia Viterbo More articles by this author Richard E. Greenberg More articles by this author David Y.T. Chen More articles by this author Robert G. Uzzo More articles by this author Alexander Kutikov More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

You have accessJournal of UrologyBladder Cancer: Detection & Screening1 Apr 2014MP22-13 HOW SAFE IS EXTENDED PHARMACOLOGICAL VENOUS THROMBOEMBOLISM PROPHYLAXIS (EPVTEP) FOR PATIENT UNDERGOING RADICAL CYSTECTOMY? Reza Mehrazin, Zachary Piotrowski, Brian Egleston, Daniel Parker, Jeffrey J. Tomaszewski, Marc C. Smaldone, Paul Bloch, Kevan Iffrig, Philip Abbosh, Timothy Ito, Rosalia Viterbo, Richard E. Greenberg, David Y.T. Chen, Robert G. Uzzo, and Alexander Kutikov Reza MehrazinReza Mehrazin More articles by this author , Zachary PiotrowskiZachary Piotrowski More articles by this author , Brian EglestonBrian Egleston More articles by this author , Daniel ParkerDaniel Parker More articles by this author , Jeffrey J. TomaszewskiJeffrey J. Tomaszewski More articles by this author , Marc C. SmaldoneMarc C. Smaldone More articles by this author , Paul BlochPaul Bloch More articles by this author , Kevan IffrigKevan Iffrig More articles by this author , Philip AbboshPhilip Abbosh More articles by this author , Timothy ItoTimothy Ito More articles by this author , Rosalia ViterboRosalia Viterbo More articles by this author , Richard E. GreenbergRichard E. Greenberg More articles by this author , David Y.T. ChenDavid Y.T. Chen More articles by this author , Robert G. UzzoRobert G. Uzzo More articles by this author , and Alexander KutikovAlexander Kutikov More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.861AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Current National Comprehensive Cancer Network and United Kingdom National Institute for Health and Clinical Excellence guidelines recommend EPVTEP of 4 weeks duration following pelvic surgery, including radical cystectomy (RC); however, this policy has not been validated. Importantly, low molecular weight heparin (LMWH) is renally cleared, and patients with GFR < 30 risk bioaccumulation and potential for hemorrhagic complications. Since RC patients often experience dehydration and secondary renal insufficiency, we sought to quantitate the risk of clinically significant renal function deterioration following RC, which could result in supratherapeutic levels of LMWH. METHODS Patients undergoing RC between 2006 and 2011 were identified from the institutional registry. GFR was calculated based on the MDRD formula and categorized as: preoperative, discharge, and nadir (lowest GFR within 90 days of discharge). Patient perioperative GFR trends in patients who would have been candidates for EPVTEP were evaluated. RESULTS 308 patients with GFR > 30 ml/min/1.73m2 at the time of hospital discharge were included in the analysis as potentially eligible for EPVTEP. Most patients were Caucasian (90%), male (73%), with a median age of 69 years old. Readmission rate for the entire cohort was 32%. Nearly half (43%) of patients exhibited decline in GFR following discharge, with the average percent drop being 14.3%. Importantly, 13.0% of patients (n=40), who would have qualified for EPVTEP at discharge, experienced nadir GRF below the 30 ml/min/1.73m2 threshold where LMWH would have become supratherapeutic (Table). CONCLUSIONS A large portion of patients (43%) undergoing RC experience GFR decline following discharge. In our cohort, 13% of candidates for EPVTEP, including those with discharge GFR >60, had a GFR decline such that LMWH, had it been given as per current recommendations, potentially would have become supratherapeutic and risked clinically significant bleeding. While post-operative VTE following RC is a recognized concern, a better understanding of risks of EPVTEP is needed before this strategy is universally adopted in patients undergoing RC. n (% of total) Patients with Nadir GFR < 30 ml/min/1.73m2 (% of group) All patients 308 (100%) 40 (13%) Patients with discharge GFR > 60 ml/min/1.73m2 231 (75%) 14 (6%) Patients with discharge GFR 40-60 ml/min/1.73m2 62 (20%) 20 (32%) Patients with discharge GFR 30-40 ml/min/1.73m2 15 (5%) 6 (40%) © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e239 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Reza Mehrazin More articles by this author Zachary Piotrowski More articles by this author Brian Egleston More articles by this author Daniel Parker More articles by this author Jeffrey J. Tomaszewski More articles by this author Marc C. Smaldone More articles by this author Paul Bloch More articles by this author Kevan Iffrig More articles by this author Philip Abbosh More articles by this author Timothy Ito More articles by this author Rosalia Viterbo More articles by this author Richard E. Greenberg More articles by this author David Y.T. Chen More articles by this author Robert G. Uzzo More articles by this author Alexander Kutikov More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Background: Double-balloon enteroscopy (DBE) is an important tool in the evaluation and management of small-bowel disease. Limited data are available on the safety, findings, and outcomes of DBE in elderly patients.Objective: To determine the safety and efficacy of DBE in elderly patients.Design: Single-center, retrospective analysis of prospectively collected database.Setting: Open-access, tertiary care referral center.Patients: A total of 176 patients undergoing DBE (216 procedures) for evaluation of small-bowel disease between August 2007 and August 2008.Interventions: Argon plasma coagulation of bleeding small-bowel lesions.Main Outcome Measurements: DBE complication rate, diagnostic/therapeutic success of DBE.Methods: An age cutoff of 75 years and older was used to designate patients as elderly. Data on complications, indications, findings, and diagnostic and therapeutic success of DBE were compared between age groups.Results: The mean age of patients was 66 +/- 16.4 years (range 20-95 years). DBE was performed in 185 patients, including 60 patients age 75 years and older and 110 patients younger than age 75. An overall complication rate of 0.9% was seen for DBE in this study, with no significant difference between age groups. No major complications were observed in elderly patients. Elderly patients were more likely to have angioectasias (39% vs 23%; P = .01) and were more likely to require endoscopic therapy during DBE (46.8% vs 29.2%; P = .01).Limitations: Single-center, retrospective study.Conclusions: DBE is safe in elderly patients. Elderly patients are more likely to have angioectasias and to require endoscopic therapy during DBE. (Gastrointest Endosc 2010;71:983-9.)

You have accessJournal of Urology1 Apr 2009RAPID DISEASE PROGRESSION IS THE PRIMARY REASON PATIENTS FAIL TO RECEIVE SYSTEMIC THERAPY FOLLOWING CYTOREDUCTIVE NEPHRECTOMY (CN) Alexander Kutikov, Robert G. Uzzo, Brian L. Egleston, Stephen A. Blakely, Kevan Iffrig, David Y.T. Chen, Rosalia Viterbo, Richard E. Greenberg, Yu-Ning Wong, and Stephen A Boorjian Alexander KutikovAlexander Kutikov More articles by this author , Robert G. UzzoRobert G. Uzzo More articles by this author , Brian L. EglestonBrian L. Egleston More articles by this author , Stephen A. BlakelyStephen A. Blakely More articles by this author , Kevan IffrigKevan Iffrig More articles by this author , David Y.T. ChenDavid Y.T. Chen More articles by this author , Rosalia ViterboRosalia Viterbo More articles by this author , Richard E. GreenbergRichard E. Greenberg More articles by this author , Yu-Ning WongYu-Ning Wong More articles by this author , and Stephen A BoorjianStephen A Boorjian More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(09)61404-XAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "RAPID DISEASE PROGRESSION IS THE PRIMARY REASON PATIENTS FAIL TO RECEIVE SYSTEMIC THERAPY FOLLOWING CYTOREDUCTIVE NEPHRECTOMY (CN)." The Journal of Urology, 181(4S), p. 497 © 2009 by American Urological AssociationFiguresReferencesRelatedDetails Volume 181Issue 4SApril 2009Page: 497 Advertisement Copyright & Permissions© 2009 by American Urological AssociationMetricsAuthor Information Alexander Kutikov More articles by this author Robert G. Uzzo More articles by this author Brian L. Egleston More articles by this author Stephen A. Blakely More articles by this author Kevan Iffrig More articles by this author David Y.T. Chen More articles by this author Rosalia Viterbo More articles by this author Richard E. Greenberg More articles by this author Yu-Ning Wong More articles by this author Stephen A Boorjian More articles by this author Expand All Advertisement PDF downloadLoading ...

Purpose: We determined whether a relationship exists between primary tumor size and histopathological features in cases of localized renal cancer.Materials and Methods: SEER data were used to create a cohort of patients who were diagnosed with localized node negative renal masses from 1988 to 2004. Nuclear grade was divided into low and high grade groups. We used a multinomial logistic model to predict the probability of nuclear grade and histological subtype with increasing primary tumor size.Results: SEER data showed that 19,932 patients with localized renal masses were evaluated. The overall nuclear grade distribution was 80% and 20% for low and high grade tumors, respectively. A multinomial logistic model revealed that the probability of a high grade tumor increased with size. For each I cm increase in size of a primary localized renal cell carcinoma the odds of high grade disease increased by 13% (OR 1.13, p <0.001). Multinomial models also predicted that the odds of papillary vs clear cell renal cell carcinoma decreased with tumor size. Conversely the odds of chromophobe vs clear cell renal cell carcinoma increased with increasing tumor size.Conclusions: Most localized node negative renal cell carcinomas are low grade. Although the probability of a high grade tumor increases with size, almost 85% of renal cell carcinomas smaller than 4 cm and 70% of localized renal cell carcinomas larger than 7 cm demonstrate low nuclear grade. The probability of detecting particular histological subtypes also varies with increasing tumor size. These data suggest that many localized renal tumors can grow large locally without acquiring metastatic potential.

Introduction: Double Balloon Enteroscopy (DBE) is a useful modality in the diagnostic evaluation and treatment of obscure GI bleeding and small bowel pathology. Limited data are available on the safety of DBE in older patients. In this study we report our single center experience over a 1 year time period. Aim: To determine the relative safety of DBE in patients over and under the age of 75 yrs. Methods: Retrospective review of DBE procedures at our center between August 2007 and August 2008 in patients over and under the age of 75 yrs. Results: A total of 216 DBE procedures in 170 patients (87 male) were reviewed. The mean age of patients studied was 66 +/- 16.4 yrs. (range 20-95 yrs.). Within this group 60 patients (79 procedures) were > age 75 yrs. A total of 2 adverse events were seen (1 patient with hypoxia and 1 patient with a transient cardiac arrhythmia). Both of these adverse events occurred in patients age 75 yrs. There were no perforations and no deaths in either group. There were no significant differences in procedure times for upper DBE (p=0.76) and lower DBE (p=0.89) in patients over and under the age of 75. Finally, there were no significant differences in depth of insertion/extent of small bowel examined for upper DBE (p=0.34) and lower DBE (p=0.47) in both groups. These data are summarized in the table below. Conclusion: DBE is safe in patients over the age of 75 yrs. There does not appear to be a significant difference in procedure times and extent of small bowel examined in patients over and under the age of 75 yrs. Tabled 1 All pts. Age <75 Age >75 # pts. 170 110 60 # procedures 216 137 79 Adverse Events 2/216 (0.9%) 2/137 (1.4%) 0/79 (0%) Upper DBE Mean Procedure Time (min) 67.9 +/- 20.4 68.2 +/- 22.6 67.2 +/- 16.3 Lower DBE Mean Procedure Time (min) 67.3 +/- 22.9 67.6 +/- 24.2 66.7 +/- 20.7 Mean Depth of insertion Upper DBE (cm) 218.3 +/- 96.6 225 +/- 97.5 208 +/- 94.2 Mean Depth of insertion Lower DBE (cm) 107.8 +/- 82.7 112 +/- 75.72 98 +/- 99.03 Open table in a new tab

Introduction: Conventional ERCP in patients with Roux-en-Y and post-Whipple anatomy is technically challenging and in some cases not feasible. Overtube-assisted techniques including double-balloon ERCP (DB ERCP) and Spirus overtube-assisted ERCP (Spirus ERCP) using a forward-viewing enteroscope can allow for deep intubation of the afferent limb facilitating pancreatico-biliary intervention in these patients. Aim: To assess the efficacy and safety of overtube-assisted ERCP in patients with surgically altered anatomy.

Introduction: DBE is useful in the diagnostic evaluation and treatment of obscure GI bleeding and small bowel pathology. Limited data are available on indications, findings and agreement between DBE and video capsule endoscopy (CE) in older patients. Aim: To evaluate the distribution of indications, findings and overall agreement of DBE with CE in patients according to age (< or > 75 years). Methods: Retrospective review of DBE procedures at our center between August 2007 and August 2008 in patients divided by age (< and > 75 years). Results: A total of 216 DBE procedures in 170 patients (87 male, 144 White) were reviewed. The mean age of patients studied was 66 +/- 16.4 yrs. (range 20-95 yrs.). Within this group, 60 patients (79 procedures) were > age 75. The most common indications for DBE in patients > age 75 were obscure GI bleeding (96%) and abnormal CE (70.9%). The most common indications for DBE in patients < age 75 were obscure GI bleeding (79.6%), abnormal CE (66.4%), and abnormal SBFT/CT/MRI (14.6%). A higher percentage of patients > age 75 were on anti-platelet medications (42% vs. 33.6%) and anti-coagulation therapy (26.7% vs. 11.8%) compared to patients < age 75. The most common DBE findings in patients > age 75 were angioectasia (39%), erosion/ulcer (10.1%), and polyp/mass (9%). The most common DBE findings in patients < age 75 were angioectasia (23%), polyp/mass (14%), and erosion/ulcer (11.5%). In patients > age 75 there was agreement between DBE findings and CE findings in 19/43 patients (44.1%). In patients < age 75 there was agreement between DBE findings and CE findings in 23/72 patients (31.9%). Endoscopic therapy was indicated in 38/79 (48.1%) procedures for patients > age 75 and 45/137 (32.8%) procedures for patients < age 75. Endoscopic therapy was successful in 32/38 (84.2%) cases for patients > age 75 and 34/45 (75.6%) for patients < age 75. Conclusions: A greater percentage of patients > age 75 have angioectasias, and are more likely to require endoscopic therapy than younger patients, while patients < age 75 have a higher percentage of polyps/mass lesions found on DBE. The agreement between findings on DBE and prior abnormal CE are relatively low in both age groups. In patients > 75 the greater likelihood of finding angioectasias requiring therapy suggests that an earlier role for DBE in elderly patients may be appropriate.

You have accessJournal of Urology1 Apr 2008RELATIONSHIP OF TUMOR SIZE AND GRADE IN LOCALIZED RENAL CELL CARCINOMA: A SEER ANALYSIS Jason R Rothman, Yu-Ning Wong, Brian L Egleston, Kevan Iffrig, Steve Lebovitch, and Robert G Uzzo Jason R RothmanJason R Rothman More articles by this author , Yu-Ning WongYu-Ning Wong More articles by this author , Brian L EglestonBrian L Egleston More articles by this author , Kevan IffrigKevan Iffrig More articles by this author , Steve LebovitchSteve Lebovitch More articles by this author , and Robert G UzzoRobert G Uzzo More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(08)61110-6AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "RELATIONSHIP OF TUMOR SIZE AND GRADE IN LOCALIZED RENAL CELL CARCINOMA: A SEER ANALYSIS." The Journal of Urology, 179(4S), p. 379 © 2008 by American Urological AssociationFiguresReferencesRelatedDetails Volume 179Issue 4SApril 2008Page: 379 Advertisement Copyright & Permissions© 2008 by American Urological AssociationMetricsAuthor Information Jason R Rothman More articles by this author Yu-Ning Wong More articles by this author Brian L Egleston More articles by this author Kevan Iffrig More articles by this author Steve Lebovitch More articles by this author Robert G Uzzo More articles by this author Expand All Advertisement PDF downloadLoading ...

Colombo, Joe; Iffrig, Kevan; Aysin, Elif; Aysin, Ben; Wo, Charles C; Shoemaker, William C; Colombo, Adam Author Information